Abstract
Objectives To report the incidence and progression rate of diabetic retinopathy (DR) and blindness in Indonesian adults with type 2 diabetes. Methods This was a prospective cohort study of 899 adults aged >30 years with confirmed type 2 diabetes. All participants underwent standardized clinical and eye examinations. Two-field retinal photographs were taken. DR was graded by trained grader masked to participants’ clinical details. We categorized DR as follows: mild, moderate, severe non-proliferative (NPDR), and proliferative DR (PDR). Additional category of vision-threatening DR (VTDR) included severe NPDR or more, or moderate NPDR with clinically significant macular edema. Blindness was defined as visual acuity £3/60. At least 1-step progression was categorized as DR progressing. Cox-proportional hazard model was used. Results The incidence and progression of DR were 34.6 and 35.1, and incidence of VTDR and blindness were 24.5 and 8.33/1000 person-years, respectively. Longer diabetes duration was associated with increasing the risk of developing DR (Hazard ratio 1.37 [95% confidence interval 1.10-1.72]) and VTDR (2.00 [1.60-2.50]) and progressing DR (1.50 [1.23-1.84]) in 5 years. Obesity was associated with increased risk of developing DR (1.75 [1.14-2.68]) and the presence of gangrene (2.54 [1.49-4.35]) and neuropathy (1.50 [1.07-2.10]) at baseline increased the risk of progressing DR in 5 years. Living in rural area was associated with increased risk of blindness (2.50 [1.03-5.88]). Conclusions We reported the incidence and progression rate of DR, VTDR, and blindness, and documented that longer diabetes duration increased the risk of DR and VTDR in 5 years.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical clearance, information sheet and consent form were approved by the Medical and Health Ethics Research Committee, Faculty of Medicine, Public Health, and Nursing, Unversitas Gadjah Mada (Ethics approval no. KE/FK/0431/EC/2019). Written informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos